- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
IOL Chemicals and Pharmaceuticals begins commercial production of Paracetamol
Paracetamol, also known as Acetaminophen, is an Active Pharma Ingredient (API) that is used to treat fever and mild pain.
Punjab: IOL Chemicals and Pharmaceuticals Limited has announced that the company has commenced the commercial production of 'Paracetamol' with installed capacity of 1800 MTPA along with backward integration of Para Amino Phenol (PAP) with effect from 22 nd April 2022.
The Company is manufacturing Paracetamol in its existing Unit No 4, which has been converted as multiproduct facility, with a cost of about Rs 100 Lakhs whereas PAP is being manufactured in part of Unit No 9. The Company shall continue to use Unit 4 & Unit 9 for manufacturing other products as per market conditions.
Further, considering the present market scenario, the Company is in the process of enhancing the installed capacity for manufacturing the Paracetamol from 1800 MTPA to 3600 MTPA with a capex of about Rs 25 Crore, which is expected to be completed during the 3 rd quarter of FY 2023. All the capex is being met through internal accruals only.
The Paracetamol, also known as Acetaminophen, is an Active Pharma ingredient (API) that is used to treat fever and mild pain, whereas PAP is used as an intermediate to manufacture Paracetamol.
Read also: IOL Chemicals gets Korean approval for Ibuprofen, Fenofibrate
IOL Chemicals and Pharmaceuticals Limited is an innovation-driven Bulk Drug, Intermediates and Specialty Chemicals Company headquartered in India. Its APIs portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. The company is the backward integrated company producing all Intermediates and Key Starting Materials (KSMs) of ibuprofen.
Read also: USFDA gives its nod to IOL chemicals and pharmaceuticals for a plant in Punjab
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751